JMP rates ViroPharma at buy

ViroPharma Inc. was given a buy rating by JMP Securities analyst Adam Cutler after the company reported third-quarter sales of $55.1 million, beating the analyst's estimate of $46 million and the Street estimate of $45 million. Earnings per share of $0.33 also beat JMP's and the Street's forecasts. ViroPharma's channel inventory build-up resulted in an extra $8 million in sales for the quarter. Look for results of the phase 3 study of HCV-796 for the treatment of hepatitis C to be a big catalyst in 2007. Shares of the Exton, Pa.-based pharmaceutical company were up 12 cents, or 0.94%, at $12.90. (Nasdaq: VPHM)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.